Biogen Inc (NASDAQ:BIIB) CEO Michel Vounatsos bought 780 shares of the firm’s stock in a transaction dated Saturday, December 29th. The shares were acquired at an average price of $320.55 per share, for a total transaction of $250,029.00. Following the completion of the transaction, the chief executive officer now owns 4,879 shares in the company, valued at approximately $1,563,963.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Michel Vounatsos also recently made the following trade(s):
- On Friday, December 29th, Michel Vounatsos purchased 780 shares of Biogen stock. The stock was purchased at an average price of $320.55 per share, for a total transaction of $250,029.00.
Shares of Biogen Inc (BIIB) opened at $339.99 on Friday. The firm has a market cap of $71,870.42, a P/E ratio of 20.85, a P/E/G ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $348.84.
BIIB has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “hold” rating and issued a $279.00 price target on shares of Biogen in a research report on Tuesday, October 24th. Royal Bank of Canada restated a “hold” rating and issued a $315.00 price target on shares of Biogen in a research report on Thursday, October 5th. Oppenheimer set a $350.00 price target on shares of Biogen and gave the company a “buy” rating in a research report on Tuesday, November 28th. Canaccord Genuity initiated coverage on shares of Biogen in a research report on Friday, October 27th. They issued a “hold” rating and a $340.00 price target on the stock. Finally, Sanford C. Bernstein set a $318.00 price target on shares of Biogen and gave the company a “buy” rating in a research report on Tuesday, November 28th. Ten equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $350.13.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Atlantic Trust LLC acquired a new position in Biogen during the second quarter valued at approximately $114,000. Horan Capital Advisors LLC. acquired a new position in shares of Biogen in the third quarter valued at approximately $128,000. Massey Quick Simon & CO. LLC boosted its holdings in shares of Biogen by 84.8% in the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 195 shares during the period. Gs Investments Inc. acquired a new position in shares of Biogen in the second quarter valued at approximately $136,000. Finally, Thompson Siegel & Walmsley LLC boosted its holdings in shares of Biogen by 33.3% in the second quarter. Thompson Siegel & Walmsley LLC now owns 528 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 132 shares during the period. Hedge funds and other institutional investors own 88.11% of the company’s stock.
WARNING: “Biogen Inc (BIIB) CEO Buys $250,029.00 in Stock” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.com-unik.info/2018/01/05/biogen-inc-biib-ceo-buys-250029-00-in-stock.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
What are top analysts saying about Biogen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biogen and related companies.